Benzhydrocodone

Benzhydrocodone (INN; contracted from benzoate-hydrocodone) is an opioid prodrug of the morphinan class.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Benzhydrocodone (INN; contracted from benzoate-hydrocodone) is an opioid prodrug of the morphinan class. Its chemical structure consists of hydrocodone coupled with benzoic acid. Benzhydrocodone itself is inactive and acts as a prodrug to hydrocodone upon cleavage of the benzoate portion of the molecule.

It is designed to be an opioid analgesic with a low chance of recreational use. Created by Kempharm, Inc., a biopharmaceutical company in Coralville, Iowa, President and CEO, Travis Mickle, believes the molecular-based approach to abuse deterrent may be more effective than many formulation-based approaches.

When approved, Apadaz received a labeling that highlighted all relevant aspects of the drug, including the lower abuse profile compared to traditional hydrocodone-acetaminophen. The labeling showed several items supporting a lower abuse profile than traditional hydrocodone-acetaminophen; namely, a lower Drug Liking in the first two hours after intranasal abuse (snorting), and the conversion of benzhydrocodone to hydrocodone in vitro being a "difficult process" — with benzhydrocodone being a more difficult drug to abuse according to FDA advisory committee documents.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1368794738 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

6 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.